<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We assessed the diagnostic usefulness of adding anti-CD117 to our existing flow cytometric profile in the analysis of 150 consecutive cases of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (de novo or relapsed <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>], <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> arising in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> of <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> [<z:mp ids='MP_0005481'>CML</z:mp>], <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, <z:hpo ids='HP_0011009'>acute</z:hpo> unclassifiable <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and biphenotypic <z:hpo ids='HP_0001909'>leukemia</z:hpo>) </plain></SENT>
<SENT sid="1" pm="."><plain>CD117 was expressed on more than 10% of blasts in 64% of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e> (42/66), 95% of relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e> (19/20), 75% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e> arising from a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (6/8), and 25% of myeloid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> in <z:mp ids='MP_0005481'>CMLs</z:mp> (1/4) </plain></SENT>
<SENT sid="2" pm="."><plain>CD117 was not expressed in <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic, <z:hpo ids='HP_0011009'>acute</z:hpo> biphenotypic, or unclassified <z:hpo ids='HP_0001909'>leukemia</z:hpo> or lymphoid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> of <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The specificity, positive predictive value, sensitivity, and negative predictive value of CD117 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were 100%, 100%, 69%, and 62%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>CD117 is a specific marker for myeloblastic <z:hpo ids='HP_0001909'>leukemias</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Sensitivity is greatest in French-American-British M2 and relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Intensity of CD117 expression is dim </plain></SENT>
<SENT sid="7" pm="."><plain>Despite the high specificity and positive predictive value, the addition of anti-CD117 to our panel did not prove essential for the assignment of blast lineage </plain></SENT>
</text></document>